Applied Micro's (NASDAQ:AMCC) management appears to believe that it can pull the wool over investors' eyes regarding its fabled X-Gene strategy indefinitely. Unfortunately, as I listened to the Q&A, none of my criticisms of the Applied Micro executive team were quelled. In fact the vague, PR-like responses to questions regarding its upcoming "X-Gene" product lend further credibility to my case that at the end of the day, X-Gene will be a textbook example of "over promise, under deliver."
Brushing Off The Intel Threat
Consider the following question posed by Patrick Wang of Evercore Partners from the latest conference call,
When we take a look at X Gene over the course of this year you'll have a 40-nanometer...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|